Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Investment includes a complete rebuild of the plant’s furnace and improvement of the plant’s facilities.
May 23, 2024
By: Charlie Sternberg
SGD Pharma, a global provider of primary glass packaging for pharmaceutical and cosmetic products, has invested more than €20 million ($21.7 million) to upgrade its Zhanjiang plant in China, including a complete rebuild of its furnace and comprehensive improvement of the plant’s facilities. Using advanced design and technologies, this new furnace allows the Zhanjiang plant to increase capacity, improve energy performance and minimize energy consumption, reducing the Group’s carbon footprint in line with its environmental commitments and long-term decarbonization roadmap. SGD Pharma’s objective is to reduce CO2 emissions from 2020 by 35% in 2030 and by 65% in 2040. Alongside the furnace rebuild, production lines and inspection equipment at the plant have been upgraded to improve glass quality and production flexibility. The plant now offers feeder coloration and a range of colored glass options to meet specific requirements, mainly for luxury beauty products. Chunyan Zheng, Deputy General Manager at SGD Pharma Zhanjiang plant, said: “This significant investment allows us to improve the operational excellence of Zhanjiang plant making sure that we manufacture the best in quality to serve our customers worldwide. We are delighted with the improvements to our plant and are excited about the new features that we can now provide our customers.” Frédéric Barbier, General Manager of SGD Pharma BU APAC, added: “SGD Pharma has been working with the Science Based Targets initiative (SBTi) on the reduction of CO2 emissions and has developed a 1.5°C decarbonization pathway and target validation. The Zhanjiang plant is a critical part of this ambitious decarbonization plan. It is fantastic to see our new furnace working in a way that helps us to not only increase productivity but also minimize environmental impact. This €20 million renovation project illustrates our sustained investment strategy, and ongoing commitment towards a more sustainable future.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !